Psilocybin

A new analysis of clinical trial data indicates that psilocybin-assisted psychotherapy provides immediate relief for anxiety and depression in advanced cancer patients, though the antidepressant effects may not persist without specific dosing strategies.

A moderate dose of psilocybin may offer temporary relief for obsessive-compulsive disorder, according to new research. The study indicates that the drug tends to reduce symptom severity for up to one week, specifically regarding compulsive behaviors.

Scientists have observed how psilocybin rewires the brain to overcome fear. The drug coordinates the silencing of trauma neurons and the activation of safety signals to promote behavioral flexibility in mice.

Nootropic gummies, marketed as mental enhancers, are sending consumers to the hospital with seizures and vomiting. An unregulated market means these products can contain undisclosed toxic mushrooms or other potent drugs, posing a serious public health risk.

A new study details how the psychedelic psilocin excites specific neurons in the prefrontal cortex. This finding helps explain how the compound may exert its potential therapeutic effects.

A treatment for depression involving just two doses of psilocybin may have effects that last for years. A new follow-up study found that two-thirds of participants were still in remission five years after their therapy, pointing to its potential durability.

Psilocybin therapy may reduce suicidal thoughts in people with mental health diagnoses, according to a new review in Therapeutic Advances in Psychopharmacology. The analysis combined results from clinical trials and found a modest but significant reduction in suicidal ideation.

In a pilot study, physicians and nurses who took part in mindfulness training combined with psilocybin therapy experienced greater reductions in depression symptoms than those who practiced mindfulness alone, offering preliminary evidence for a new approach to burnout treatment.

A small pilot study found that a single 25 mg dose of psilocybin led to lasting reductions in depression symptoms among U.S. military veterans with treatment-resistant depression. Half were in remission after six months; 30% remained in remission at one...

A groundbreaking study has revealed that classical psychedelics affect far more than just serotonin. By mapping how 41 compounds interact with brain receptors, researchers challenge long-held assumptions and open new directions for psychedelic science and therapeutic development.

Cancer patients with major depression experienced significant and long-lasting improvements after just one psilocybin session, according to new research. Two years later, many showed continued reductions in depression and anxiety, with some requiring no further treatment or medication.

Psilocybin and MDMA may do more than alter perception. A study in Nature suggests they also reduce fear by targeting a newly identified immune-brain signaling loop, which becomes hyperactive under chronic stress and contributes to heightened fear responses.

A groundbreaking study has found that psilocybin can profoundly affect religious leaders, enhancing their spiritual lives and emotional well-being. Six months after two guided sessions, clergy from major world religions reported lasting positive changes in faith, mood, and leadership effectiveness.

Scientists have discovered that psilocybin may have powerful anti-aging properties. New research provides the first experimental evidence that the compound from psychedelic mushrooms extends survival in aged mice and significantly delays the natural aging process in human cells.

Researchers have discovered that psilocybin—but not ketamine—triggers widespread changes in neuropeptide-related genes in the rat hypothalamus. These findings may help explain how psychedelics influence mood, appetite, and stress responses through deep brain systems.